Chemotherapy is the initial standard-of-care treatment for unresectable (stage IIIB/IV) non-small cell lung cancer (NSCLC). Based upon historical information, the optimal duration of initial therapy with a platinum doublet (two-drug regimen) is 4-6 cycles. The addition of bevacizumab (Avastin) to the carboplatin and paclitaxel first-line treatment regimen has improved progression free survival (PFS) from 4.5 (placebo) to 6.2 months (bevacizumab) (ECOG 4599, Sandler et al NEJM 355: 2542-2550, 2006). Longer therapy initial therapy has, in some cases, improved progression free survival (PFS), without improvement in overall survival (OS). That may be a result of the benefit of second-line treatment (at the time of progression), which may also extend overall survival (OS).
The benefit of maintenance therapy, after initial treatment, was examined by a group of international investigators, reported by Dr. Ciuleanu (Romania) at the 2008 ASCO Annual Meeting (J Clin Oncol 26: 2008 (May 20 suppl; abstr 8011)). Patients received initial chemotherapy, and then the patients were randomly assigned to maintenance therapy with pemetrexed (Alimta) or placebo. The study demonstrated a significant improvement in PFS for the patients who received maintenance pemetrexed therapy, with PFS of 4 months (versus 2 months for placebo). In the subset analysis, patients with non-squamous cell histology benefited, while squamous cancers did not. The observation that response to pemetrexed was superior in non-squamous histology lung cancer has been observed in two previous investigations. This study also demonstrated a strong trend (nearing statistical significance) for improved overall survival (OS) in patients with non-squamous histology who received pemetrexed maintenance therapy. The final results of OS in this study have not yet been reported.
The use of maintenance pemetrexed with bevacizumab was also reported at the ASCO 2008 Annual Meeting (J Clin Oncol 26: 2008 (May 20 suppl; abstr 8044)). Dr. Patel reported the results of a study in which all patients received carboplatin and pemetrexed with bevacizumab as initial therapy x 6 cycles. Patients without progression continued on pemetrexed and bevacizumab for maintenance therapy every 3 weeks. This was a single arm study. The PFS was 9.2 months, and the OS was 13.5 months. Treatment with maintenance pemetrexed and bevacizumab was very well tolerated, and 60% of patients had >6 cycles, 18% had >18 cycles, and 14% had >24 cycles.
The PFS of the study reported by Patel et al are favorable. If one expects a PFS with a platinum doublet + bevacizumab of 6 months, and an additional 4 months of PFS with pemetrexed maintenance therapy, the the results of the Patel study are in line with those reporte by Ciuleanu et al. The study of Patel did give bevacizumab until progression, as was done in the ECOG 4599 study.
These studies mark continued progress in treatment of unresectable and metastatic NSCLC. Integration of anti-angiogenic therapy (bevacizumab) and less toxic treatment with new agents like pemetrexed have incrementally extended PFS. Overall survival may also be impacted.
Additional improvements may come with the integration of other sorts of maintenance treatment, for example, anti-tumor vaccine therapy. CORT is testing the anti-MUC-1 tumor vaccine, Stimuvax, as part of the START study, for patients who have completed initial chemotherapy and radiation therapy for unresectable Stage III NSCLC. Information about that study is available in another post. For further information about lung cancer therapy at CORT, including the START study, visit our webpage at www.cortpa.com, or contact a Research Coordinator at 972-566-5588.